Tirzepatide Pros and Cons: Benefits, Risks, and What to Expect

Tirzepatide's main pros are substantial, well-documented weight loss and improved blood sugar control, and its main cons are gastrointestinal side effects, high cost, and weight regain after stopping. It is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, and both are FDA-approved prescription medicines in the United States. Below is a balanced look at the tirzepatide pros and cons, including who should avoid it and how it compares with other options.

What Tirzepatide Is and How It Works

Tirzepatide is a once-weekly injection that activates two hormone receptors: GIP and GLP-1. Those gut hormones help regulate appetite, digestion, and insulin release.

By slowing how quickly the stomach empties and increasing feelings of fullness, tirzepatide typically reduces how much a person eats. Doses start low and step up roughly every four weeks, topping out at 15 mg per week, to limit side effects.

Tirzepatide is not a cure for obesity or diabetes. It works best alongside nutrition changes, physical activity, and routine medical follow-up.

The Pros of Tirzepatide

• Among the largest weight losses seen in trials. In SURMOUNT-1, adults without diabetes lost roughly 15% to 21% of their body weight over 72 weeks at the highest doses.
• Stronger average results than semaglutide in a head-to-head study. In SURMOUNT-5, tirzepatide produced about 20% weight loss versus roughly 14% for semaglutide at 72 weeks.
• Meaningful blood sugar improvement. In people with type 2 diabetes, tirzepatide lowers A1C, and it has been studied for cardiovascular outcomes.
• Once-weekly dosing. One injection per week is easier to maintain than daily injections for many people.
• An additional FDA-approved use. Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, a first for this drug class.

The Cons of Tirzepatide

• Gastrointestinal side effects are common. Nausea, vomiting, diarrhea, constipation, and abdominal pain affect many users, especially during dose increases.
• The cost is high. List prices exceed $1,000 per month without insurance, though savings programs and cash-pay vials have lowered some patients' bills.
• Weight often returns after stopping. In SURMOUNT-4, participants regained about two-thirds of their lost weight within a year of discontinuing the drug.
• Lean muscle mass can decline. Rapid weight loss may include muscle, which is why adequate protein and resistance training matter.
• Rare but serious risks exist. These include pancreatitis, gallbladder disease, bowel obstruction, kidney injury from dehydration, and severe low blood sugar when combined with insulin or sulfonylureas.
• Pregnancy and surgery considerations. Tirzepatide is not recommended during pregnancy, and guidance generally advises pausing it before planned surgery to reduce aspiration risk.

Tirzepatide vs. Semaglutide at a Glance

Feature	Tirzepatide (Mounjaro, Zepbound)	Semaglutide (Ozempic, Wegovy)
Mechanism	Dual GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
Typical dosing	Once-weekly injection	Once-weekly injection (oral form exists for diabetes)
Average weight loss without diabetes	About 15% to 21% at 72 weeks	About 15% at 68 weeks
FDA weight management approval	Zepbound, for adults with obesity or overweight plus a related condition	Wegovy, for the same adult criteria
Most common side effects	Nausea, diarrhea, vomiting, constipation	Nausea, diarrhea, vomiting, constipation

Anyone sorting through GLP-1 choices usually weighs the semaglutide pros and cons right next to tirzepatide's, since the two drugs are the most direct competitors in this category.

Cost, Access, and Compounded Alternatives

Insurance coverage for tirzepatide varies widely, and many plans require prior authorization or a documented type 2 diabetes diagnosis. Without coverage, monthly out-of-pocket costs often exceed $1,000.

Compounded tirzepatide became far harder to obtain after the FDA declared the shortage resolved in late 2024, and the legal landscape has shifted through ongoing litigation. Compounded products are not FDA-approved and may differ in purity, dose, and labeling.

Broader curiosity about the pros and cons of peptides for weight loss often leads people toward non-approved compounds with thin human data. Searches for aod-9604 and tirzepatide together reflect interest in stacking, but no human trials support that pairing, and the peptide injections pros and cons generally come down to convenience versus cost, purity, and oversight.

Who Should Not Use Tirzepatide

• People with a personal or family history of medullary thyroid cancer or MEN2
• People with prior pancreatitis or severe gastroparesis
• Anyone pregnant, breastfeeding, or planning pregnancy
• People with type 1 diabetes, since it has not been studied for that use
• Adults taking insulin or sulfonylureas without a dose review, because of low blood sugar risk

The Bottom Line on Tirzepatide

• Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management in adults in the United States.
• Tirzepatide tends to produce greater average weight loss than semaglutide, but individual results and tolerability vary.
• Most people regain a large share of lost weight after stopping tirzepatide, so it is generally treated as a long-term therapy.
• Gastrointestinal side effects are the most common reason people stop tirzepatide.
• Tirzepatide is not a cosmetic shortcut and is not a replacement for medical supervision.

Talk with a healthcare professional about your health history, current medications, and goals before starting or stopping any weight management medication.

COMMON QUESTIONS

Frequently Asked Questions

Is tirzepatide or semaglutide better for weight loss?

In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide: about 20% versus roughly 14% of body weight at 72 weeks. Individual responses and side effects still vary, and insurance coverage often influences which drug a patient can actually get.

What are the most common side effects of tirzepatide?

Nausea, diarrhea, vomiting, constipation, and abdominal pain are the most frequently reported side effects. They are usually worst during the first weeks and after each dose increase, and many people find they ease over time. Severe or persistent symptoms should be reported to a doctor.

Do you gain weight back after stopping tirzepatide?

Yes, most people regain a significant portion of the weight they lost. In the SURMOUNT-4 trial, participants regained about two-thirds of their lost weight within a year after stopping the drug. That is why tirzepatide is generally framed as an ongoing treatment rather than a short-term fix.